Find trials
Search tips

Prediction Of Adverse Outcomes Following TAVI

Overview

About this study

The purpose of this study is to calculate biological age among 600 patients undergoing TAVI (≥65 years) over 2 years, through deficits estimation (presence or alterations in functional, psychosocial, and traditional cardiovascular deficits). Biological aging will be defined as deficit index (deficits present/deficits measured) and would be counted by simply adding them. We will then build and internally validate a composite predictor of biological aging that is simple, practical, and inexpensive.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients ≥65 years after TAVI.

Exclusion Criteria:

  • History of stroke with significant residual neurologic deficit; severe dementia; severe Parkinson’s disease; life expectancy <1 year; known drug/alcohol dependence.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 5/28/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Mandeep Singh, M.D.

Contact us for the latest status

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20598360

Mayo Clinic Footer